*2.2.1 Nivolumab*

Trade name Opdivo (Bristol-Meyers Squib) is a PD-1-blocking antibody. It is administered via intravenous infusion, currently approved for metastatic melanoma, non-small-cell lung cancer, metastatic small-cell lung cancer, metastatic squamous cell carcinoma of the head and neck, urothelial cancer, hepatocellular carcinoma, Hodgkin lymphoma, and metastatic colorectal cancer. Nivolumab has numerous approved indications to be used in combination with other therapies, including anti-CTLA-4

Ipilimumab. Nivolumab + Ipilimumab combination is approved for metastatic melanoma and renal cell carcinoma.

## *2.2.2 Pembrolizumab*

Trade name Keytruda (Merck) is a PD-1-blocking antibody. It is administered via intravenous infusion, currently approved for melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal B-cell lymphoma, urothelial carcinoma, metastatic colon and rectal cancer, unresectable or metastatic solid tumors with high microsatellite instability, PD-L1 positive cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, and advanced endometrial carcinoma. Pembrolizumab is the only approved ICI to demonstrate objective tumor regression [12].

## *2.2.3 Cemiplimab*

Trade name Libtayo (Regeneron/Sanofi Genzyme) is a PD-1-blocking antibody. It is administered via intravenous infusion, currently approved for metastatic or advanced cutaneous squamous cell carcinoma and non-small cell lung cancer.

## *2.2.4 Avelumab*

Trade name Bavencio (EMD Serono & Pfizer) is a PD-L1-blocking antibody. It is administered via intravenous infusion and is currently approved for urothelial and renal cell carcinoma.

## *2.2.5* Durvalumab

Trade name Imfinzi (AstraZeneca) is a PD-L1-blocking antibody. It is administered via intravenous infusion and approved for the treatment of unresectable stage III non-small cell lung cancer, extensive-stage small cell lung cancer and for bile duct and gallbladder cancer.

## *2.2.6 Atezolizumab*

Trade name Tecentriq (Genentech) is a PD-L1-blocking antibody. It is administered via intravenous infusion. It is approved for the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.
